Thema: US09058V1035
BCRX, US09058V1035
business-21681_1920.jpg - Foto: THN
BioCryst stock: Wedbush trims valuation target
Wedbush kept its Outperform rating after lowering the target from USD 20.00 to USD 18.00. BioCryst stock now has a more cautious analyst marker ahead.
ad-hoc-news.de, 30.10.26 20:33 Uhr
BCRX, US09058V1035
Wedbush cuts target for BioCryst stock from USD 20.00 to ...
2026 second-quarter revenue reached USD 218.25 million. BioCryst stock costs EUR 7.18 on October 27, 2026, up 2.57 percent versus the Frankfurt close.
ad-hoc-news.de, 27.10.26 21:59 Uhr
BCRX, US09058V1035
TD Cowen maintains USD 30.00 target for BioCryst Pharmaceuticals ...
FDA approved 150 mg ORLADEYO granules on October 21, 2026. BioCryst Pharmaceuticals stock costs EUR 6.83 on October 24, 2026 at 1:04 p.m. CEST.
ad-hoc-news.de, 24.10.26 18:50 Uhr
BCRX, US09058V1035
BioCryst stock: BioCryst announces November 4 results date ...
Second-quarter 2026 revenue reached USD 218.25 million. BioCryst stock costs EUR 6.89 on October 22, 2026 at 11:45 p.m. CEST in late trading.
ad-hoc-news.de, 22.10.26 21:54 Uhr
BCRX, US09058V1035
BioCryst Pharmaceuticals stock gains 2.32 percent at EUR ...
Q2 revenue reached USD 218.25 million. BioCryst Pharmaceuticals stock costs EUR 7.06 on October 20, 2026, up 2.32 percent versus Tradegate close.
ad-hoc-news.de, 20.10.26 20:17 Uhr
BCRX, US09058V1035
RBC keeps USD 11.00 target as BioCryst stock closed at USD ...
Results are scheduled for November 2, 2026. BioCryst stock costs USD 7.79 on October 16, 2026, down 2.87 percent versus Nasdaq's close.
ad-hoc-news.de, 17.10.26 20:14 Uhr
BCRX, US09058V1035
Bank of America sets USD 15.00 target for BioCryst stock ...
Q2 revenue was USD 218.25 million, 33.60 percent above last year. BioCryst stock costs EUR 7.20 on October 15, 2026, unchanged versus Nasdaq close.
ad-hoc-news.de, 15.10.26 21:39 Uhr
BCRX, US09058V1035
BioCryst stock trades 1.47 percent below its prior close ...
BioCryst generated USD 218.25 million in the second quarter, up 33.60 percent year over year. BioCryst stock costs EUR 7.38 on October 8, 2026 after EUR 7.49.
ad-hoc-news.de, 08.10.26 19:18 Uhr
BCRX, US09058V1035
BioCryst Pharmaceuticals stock gets USD 20.50 target as ...
